LEAD VENTURES INC Financials Lead Ventures Inc Canadian Securities Exchange
Equities
LEAD
CA5542341048
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - CAD | -.--% |
|
-.--% | -37.50% |
| 05-10 | Needham Adjusts Price Target on Curaleaf to $6.25 From $5.25, Keeps Buy Rating | MT |
| 05-09 | Transcript : Curaleaf Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,995 | 7,932 | 6,327 | 3,084 | 3,052 | 4,087 | - | - |
| Enterprise Value (EV) 1 | 3,058 | 8,150 | 6,464 | 3,544 | 3,548 | 4,611 | 4,816 | 4,765 |
| P/E ratio | -42 x | -109 x | -59.6 x | -8.27 x | -10.7 x | -40.1 x | -106 x | 21.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 13.6 x | 12.7 x | 5.23 x | 2.31 x | 2.27 x | 2.9 x | 2.64 x | 2.43 x |
| EV / Revenue | 13.8 x | 13 x | 5.34 x | 2.65 x | 2.63 x | 3.28 x | 3.11 x | 2.83 x |
| EV / EBITDA | 118 x | 56.6 x | 21.7 x | 11.6 x | 11.6 x | 13.3 x | 11.8 x | 9.11 x |
| EV / FCF | -25.4 x | -71.5 x | -31.4 x | -38.5 x | 138 x | 73.4 x | 32 x | 24 x |
| FCF Yield | -3.94% | -1.4% | -3.19% | -2.59% | 0.73% | 1.36% | 3.13% | 4.17% |
| Price to Book | - | 4.84 x | 3.71 x | 2.41 x | 2.86 x | - | - | - |
| Nbr of stocks (in thousands) | 476,001 | 662,968 | 707,979 | 717,322 | 734,220 | 741,613 | - | - |
| Reference price 2 | 6.293 | 11.96 | 8.937 | 4.300 | 4.156 | 5.512 | 5.512 | 5.512 |
| Announcement Date | 24/03/20 | 09/03/21 | 03/03/22 | 01/05/23 | 06/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 221 | 626.6 | 1,210 | 1,336 | 1,347 | 1,407 | 1,546 | 1,684 |
| EBITDA 1 | 25.9 | 144.1 | 298 | 305.4 | 304.5 | 346.9 | 409.7 | 523.2 |
| EBIT 1 | -27.72 | 63.68 | 175.6 | -12.37 | 42.88 | 132.6 | 202.8 | 333.7 |
| Operating Margin | -12.54% | 10.16% | 14.52% | -0.93% | 3.18% | 9.43% | 13.12% | 19.82% |
| Earnings before Tax (EBT) 1 | -45.79 | 22.04 | 64.8 | -226.4 | -124.4 | 56.5 | 116.8 | 264.3 |
| Net income 1 | -67.24 | -61.74 | -101.7 | -370.1 | -281.2 | -80.13 | 4.458 | 194.8 |
| Net margin | -30.42% | -9.85% | -8.41% | -27.69% | -20.88% | -5.69% | 0.29% | 11.57% |
| EPS 2 | -0.1500 | -0.1100 | -0.1500 | -0.5200 | -0.3900 | -0.1375 | -0.0522 | 0.2600 |
| Free Cash Flow 1 | -120.4 | -113.9 | -205.9 | -91.96 | 25.8 | 62.84 | 150.5 | 198.6 |
| FCF margin | -54.47% | -18.18% | -17.02% | -6.88% | 1.92% | 4.47% | 9.73% | 11.8% |
| FCF Conversion (EBITDA) | - | - | - | - | 8.47% | 18.11% | 36.74% | 37.96% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 3,376.44% | 101.98% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 24/03/20 | 09/03/21 | 03/03/22 | 01/05/23 | 06/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 320 | 313.1 | 337.6 | 339.7 | 352.5 | 336.5 | 338.6 | 333.2 | 345.3 | 338.9 | 347.2 | 354.7 | 366.2 | 366 | 375.4 |
| EBITDA 1 | 79.68 | 72.94 | 86.18 | 84.04 | 73.19 | 73.18 | 70.03 | 75.25 | 83.01 | 76.71 | 84.04 | 90.01 | 94.51 | 92.3 | 97.08 |
| EBIT 1 | 42.88 | 43.73 | 23.36 | 11.42 | -81.53 | 16.44 | -7.082 | 15.21 | 13.97 | 25.25 | 24.97 | 32.49 | 35.91 | 24.92 | 29.05 |
| Operating Margin | 13.4% | 13.97% | 6.92% | 3.36% | -23.13% | 4.89% | -2.09% | 4.57% | 4.05% | 7.45% | 7.19% | 9.16% | 9.81% | 6.81% | 7.74% |
| Earnings before Tax (EBT) 1 | 10.23 | 21.38 | 16.85 | -12.92 | -249.2 | -5.667 | -27.48 | -35.95 | -60.63 | - | 13.24 | 16.03 | 15.82 | 8.395 | 12.55 |
| Net income 1 | -27.54 | -19.98 | -28.34 | -51.48 | -260.3 | -54.38 | -71.24 | -92.35 | -63.23 | -48.31 | -25.95 | -23.25 | -23.81 | -36.74 | -33.88 |
| Net margin | -8.61% | -6.38% | -8.39% | -15.15% | -73.85% | -16.16% | -21.04% | -27.72% | -18.31% | -14.25% | -7.48% | -6.56% | -6.5% | -10.04% | -9.03% |
| EPS 2 | -0.0400 | -0.0300 | -0.0400 | -0.0700 | -0.3600 | -0.0700 | -0.1000 | -0.1300 | -0.0900 | -0.0700 | -0.0457 | -0.0400 | -0.0429 | -0.0500 | -0.0500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 03/03/22 | 09/05/22 | 08/08/22 | 07/11/22 | 01/05/23 | 17/05/23 | 09/08/23 | 09/11/23 | 06/03/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 62.6 | 218 | 137 | 460 | 496 | 523 | 728 | 678 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.418 x | 1.513 x | 0.4589 x | 1.505 x | 1.628 x | 1.504 x | 1.777 x | 1.296 x |
| Free Cash Flow 1 | -120 | -114 | -206 | -92 | 25.8 | 57.7 | 151 | 199 |
| ROE (net income / shareholders' equity) | -15.8% | -6.91% | -3.79% | -17.9% | -24.1% | -17.8% | 8.4% | 15.9% |
| ROA (Net income/ Total Assets) | -10.3% | -3.95% | -2.06% | -7.76% | -8.64% | -9.3% | - | - |
| Assets 1 | 653.4 | 1,562 | 4,930 | 4,771 | 3,256 | 886.8 | - | - |
| Book Value Per Share | - | 2.470 | 2.410 | 1.780 | 1.450 | - | - | - |
| Cash Flow per Share 2 | -0.0800 | 0.0200 | -0.0500 | 0.0700 | 0.1300 | 0.1000 | 0.3600 | 0.5300 |
| Capex 1 | 82.1 | 126 | 172 | 138 | 65.4 | 62 | 66.5 | 200 |
| Capex / Sales | 37.13% | 20.15% | 14.22% | 10.35% | 4.86% | 4.4% | 4.3% | 11.87% |
| Announcement Date | 24/03/20 | 09/03/21 | 03/03/22 | 01/05/23 | 06/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
5.512
USD
Average target price
8.424
USD
Spread / Average Target
+52.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +131.68% | 2.07B | |
| +131.75% | 77.4M |
- Stock Market
- Equities
- CURA Stock
- LEAD Stock
- Financials Lead Ventures Inc
